Working… Menu

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00850928
Recruitment Status : Completed
First Posted : February 25, 2009
Last Update Posted : March 17, 2016
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
Postoperative cognitive dysfunction (POCD) can be a serious complication. The development of therapeutic strategies for the prevention and treatment of this condition requires the identification of subgroup of patients with the greatest incidence of POCD. Several retrospective analyses have raised the possibility that surgery is a risk factor for the accelerated progression of Alzheimer's disease (AD). Moreover, there is increasing evidence that inflammatory mechanisms are involved in the pathogenesis of AD. Major surgery can be associated with a profound systemic inflammatory response. Consequently, it is reasonable to suggest that there is a link between major surgery and the postoperative development of AD in patients who are already at high risk for this complication, e.g. the elderly with mild cognitive impairment. In addition, there are several laboratory investigations that suggest that anesthetic agents increase amyloid peptide levels as well as enhance oligomerization of these proteins. The significance of these findings, however, is unknown. This clinical study seeks to correlate perioperative inflammatory responses, perioperative changes in amyloid-beta protein levels (markers of AD) with neurocognitive and functional outcome in the elderly who are at risk for POCD. This knowledge does not exist, but is essential in the effort to plan perioperative care that can reduce the incidence of POCD as well as improve functional recovery.

Condition or disease
Postoperative Cognitive Dysfunction Mild Cognitive Impairment

Detailed Description:

We will recruit 50 patients 65 years and older scheduled for spine surgery. The design utilizes prospective serial assessments. The enrolled 50 surgical subjects will be evaluated preoperatively and postoperatively over 6 time-points (preoperatively, inta-op, post op day 1, post op day 7, three months and six months) using a widely accepted set of neurocognitive tests, multiple indices of functional recovery, as well as blood tests for plasma biomarkers of inflammation and β-amyloids. Enrollees will be divided in 2 groups: 25 patients with mild cognitive impairment (diagnosed by clinical assessment) and 25 normal elderly patients.

The definition of normal elderly includes: 1). Global Deterioration Scale (GDS) < 3 and Mini-Mental Exam Score (MMSE) >27; 2). Performance on neurocognitive testing (including memory) that is within 1.5 Standard Deviation (SD) of the age matched normative data; 3). The informant interview confirming no functional impairment in the subject. The definition of MCI includes: self-reported memory and functional complains, a history of memory decline with functional changes that are corroborated by a knowledgeable informant, and a clinical interview resulting in a GDS=3 or higher and MMSE=26 or lower.

Layout table for study information
Study Type : Observational
Actual Enrollment : 41 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids.
Study Start Date : December 2008
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis

65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.

Primary Outcome Measures :
  1. To examine the effect of surgery on the progression of AD in a population at high risk for this disease through measures of Amyloid Beta levels (AB40 and AB42). levels [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. To determine whether major surgery induces an increase in plasma Aβ40 and Aβ42. [ Time Frame: 2 years ]
  2. To determine whether the pattern of plasma inflammatory markers is different in patients with MCI compared to patients without MCI. [ Time Frame: 2 years ]
  3. To determine whether the Apolipoprotein E genotype correlates with POCD. [ Time Frame: 2 years ]
  4. To examine the relationship between plasma levels of Aβ40 / Aβ42 and subject performance on neurocognitive testing. [ Time Frame: 2 years ]
  5. To establish a correlation between preoperative mild cognitive impaired (MCI) and post operative cognitive decline ( POCD) using neurocognitive testing. [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA
Serum and plasma will be collected and stored at baseline, intra-operatively, and one day post-operative for analysis of markers of inflammation. Plasma will be collected and stored at baseline, three months, and six months for analysis of Beta Amyloid levels. DNA will be collected and stored at baseline for analysis of Apolipoprotein E.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
65 years and older scheduled for major spinal surgery.

Inclusion Criteria:

  1. Patients age 65 and older scheduled to undergo spine surgery.
  2. Subjects who are able to read and understand English

Exclusion Criteria:

  1. Emergent nature of the procedure which might preclude the conduct of preoperative cognitive examination
  2. Participation in any other investigational intervention or clinical study
  3. History of psychiatric illnesses (except depression)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00850928

Layout table for location information
United States, New York
NYU School of Medicine
New York City, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Layout table for investigator information
Study Director: Germaine Cuff, PhD NYU School of Medicine

Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT00850928     History of Changes
Other Study ID Numbers: H08-658
First Posted: February 25, 2009    Key Record Dates
Last Update Posted: March 17, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by NYU Langone Health:
Postoperative Cognitive Dysfunction
Mild Cognitive Impairment
Apolipoprotein E
Inflammatory Markers
Apolipoprotein E Profile
Serum Beta Amyloid Profile
Inflammatory Markers Profile
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Pathologic Processes
Cognition Disorders
Neurocognitive Disorders
Mental Disorders